Retatrutide is one of the most closely studied investigational peptides in current metabolic research. This article provides an educational overview of what the published scientific literature reports about retatrutide and its mechanism of action. All information below is provided strictly for research and informational purposes.
What is Retatrutide?
Retatrutide is an investigational once-weekly peptide that acts as a "triple agonist" — meaning it activates three distinct receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This distinguishes it from earlier compounds in the same research area, such as semaglutide (a GLP-1 agonist) and tirzepatide (a GLP-1/GIP dual agonist).
Mechanism of action
The scientific interest in retatrutide stems from its unique three-receptor activity. Research literature describes the addition of glucagon-receptor activity — on top of GIP and GLP-1 — as a potential driver of increased energy expenditure, in addition to the appetite-related effects associated with the GLP-1 pathway. Preclinical studies have reported effects on gastric emptying and food intake in animal models.
What the clinical research has reported
Retatrutide has progressed through Phase 1 and Phase 2 studies and is currently the subject of the large Phase 3 TRIUMPH and TRANSCEND clinical trial programs.
Published Phase 2 data in the New England Journal of Medicine reported dose-dependent metabolic outcomes in study participants over a 48-week period. Phase 2 research published in Nature Medicine examined retatrutide's effect on liver-fat measures, reporting significant reductions across dosing groups compared with placebo. More recent Phase 3 readouts announced by the manufacturer in 2025–2026 reported continued metabolic outcomes data, with detailed results scheduled for peer-reviewed publication.
Across these studies, the reported adverse effects were predominantly gastrointestinal and described as dose-related, with a safety profile reported as broadly consistent with other incretin-based compounds in the same research class.
Regulatory status in Australia
Retatrutide is an investigational compound. As of 2026 it has not been approved by the Therapeutic Goods Administration (TGA) and is not listed on the Australian Register of Therapeutic Goods (ARTG). It is not approved for therapeutic use in any country and remains under clinical investigation.
Important disclaimer
This article is provided for informational and laboratory-research purposes only. Retatrutide is supplied strictly as a research compound, for in-vitro laboratory research use only. It is not for human or animal consumption. Nothing in this article constitutes medical advice, nor a recommendation for use in humans. Always refer to current published literature and applicable regulations.